Inflammatory biomarkers and risk of breast cancer among young women in Latin America: a case-control study.
Biomarkers
Breast cancer
Inflammation
Latin America
Premenopausal
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
11 Aug 2022
11 Aug 2022
Historique:
received:
05
05
2022
accepted:
02
08
2022
entrez:
10
8
2022
pubmed:
11
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Breast cancer incidence is increasing rapidly in Latin America, with a higher proportion of cases among young women than in developed countries. Studies have linked inflammation to breast cancer development, but data is limited in premenopausal women, especially in Latin America. We investigated the associations between serum biomarkers of chronic inflammation (interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), leptin, adiponectin) and risk of premenopausal breast cancer among 453 cases and 453 matched, population-based controls from Chile, Colombia, Costa Rica, and Mexico. Odds ratios (OR) were estimated using conditional logistic regression models. Analyses were stratified by size and hormonal receptor status of the tumors. IL-6 (OR The results of this study support the implication of chronic inflammation in breast cancer risk in young women in Latin America. Largest studies of prospective design are needed to confirm these findings in premenopausal women.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer incidence is increasing rapidly in Latin America, with a higher proportion of cases among young women than in developed countries. Studies have linked inflammation to breast cancer development, but data is limited in premenopausal women, especially in Latin America.
METHODS
METHODS
We investigated the associations between serum biomarkers of chronic inflammation (interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), leptin, adiponectin) and risk of premenopausal breast cancer among 453 cases and 453 matched, population-based controls from Chile, Colombia, Costa Rica, and Mexico. Odds ratios (OR) were estimated using conditional logistic regression models. Analyses were stratified by size and hormonal receptor status of the tumors.
RESULTS
RESULTS
IL-6 (OR
CONCLUSIONS
CONCLUSIONS
The results of this study support the implication of chronic inflammation in breast cancer risk in young women in Latin America. Largest studies of prospective design are needed to confirm these findings in premenopausal women.
Identifiants
pubmed: 35948877
doi: 10.1186/s12885-022-09975-6
pii: 10.1186/s12885-022-09975-6
pmc: PMC9367082
doi:
Substances chimiques
Biomarkers
0
Interleukin-6
0
Interleukin-8
0
Leptin
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
877Investigateurs
Jenny Tejeda
(J)
María Felix Lazcano
(MF)
Libia Zulema Franco
(LZ)
Roberto Jaramillo
(R)
Alberto Angel
(A)
Carlos Andres Ossa
(CA)
William H Arias
(WH)
Gabriel Bedoya
(G)
Alicia Cock-Rada
(A)
Carolina Echeverri
(C)
Fernando Herazo
(F)
Israel Díaz-Yunez
(I)
Angel Hernández
(A)
Bernal Cortes
(B)
Paula Gonzalez
(P)
Rebecca Ocampo
(R)
Diego Guillen
(D)
Viviana Loría
(V)
Catalina Vial
(C)
Lizette Diaz
(L)
Elizabeth Donato
(E)
Thomas Donn
(T)
Kelly Wirtala
(K)
Hailey Loucks
(H)
Informations de copyright
© 2022. The Author(s).
Références
Sci Rep. 2018 Aug 30;8(1):13109
pubmed: 30166604
J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6
pubmed: 17213279
Int J Cancer. 2004 Apr 20;109(4):507-15
pubmed: 14991571
Salud Publica Mex. 2014 Sep-Oct;56(5):547-54
pubmed: 25604300
Salud Publica Mex. 2019 Sep-Oct;61(5):601-608
pubmed: 31661737
Breast Cancer Res Treat. 2012 May;133(1):11-21
pubmed: 22057973
Eur J Cancer. 2008 May;44(7):937-45
pubmed: 18387296
Br J Cancer. 2021 Aug;125(4):495-509
pubmed: 33911195
Lancet Oncol. 2009 Jan;10(1):13-4
pubmed: 19115512
Am J Prev Med. 2014 Mar;46(3 Suppl 1):S52-64
pubmed: 24512931
Int J Epidemiol. 2014 Aug;43(4):1226-36
pubmed: 24737805
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1439-49
pubmed: 26224798
BMC Cancer. 2020 Jul 23;20(1):686
pubmed: 32703187
Nat Rev Endocrinol. 2021 Jun;17(6):350-363
pubmed: 33927368
J Cell Physiol. 2018 Dec;233(12):9716-9723
pubmed: 30078181
Rocz Akad Med Bialymst. 2003;48:82-4
pubmed: 14737948
Adv Clin Exp Med. 2017 May-Jun;26(3):421-426
pubmed: 28791816
Sci Rep. 2017 Oct 5;7(1):12708
pubmed: 28983080
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Cancer Res. 2004 Nov 1;10(21):7157-62
pubmed: 15534087
PLoS One. 2014 Feb 06;9(2):e88196
pubmed: 24516611
Medicine (Baltimore). 2017 Dec;96(49):e8840
pubmed: 29245248
Cell Oncol (Dordr). 2020 Feb;43(1):1-18
pubmed: 31900901
Am J Pathol. 2001 Feb;158(2):639-46
pubmed: 11159200
Biomark Res. 2020 Sep 29;8:49
pubmed: 33005420
Front Oncol. 2020 Apr 22;10:584
pubmed: 32391269
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Diabetologia. 2009 Nov;52(11):2345-2349
pubmed: 19756488
J Natl Cancer Inst. 2008 Mar 19;100(6):443-4; author reply 444-5
pubmed: 18334713
Cancer Prev Res (Phila). 2021 May;14(5):509-520
pubmed: 33563604
Cytokine Growth Factor Rev. 2016 Oct;31:61-71
pubmed: 27578214
Sci Rep. 2020 Feb 10;10(1):2294
pubmed: 32042008
Breast Cancer Res Treat. 2009 Feb;113(3):567-76
pubmed: 18330696
Cancer Epidemiol. 2015 Dec;39(6):831-7
pubmed: 26651442
Breast Cancer Res Treat. 1997 May;43(3):211-5
pubmed: 9150900
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Int J Environ Res Public Health. 2020 Jul 28;17(15):
pubmed: 32731638
Breast Cancer Res Treat. 2013 Apr;138(3):657-64
pubmed: 23532539
Cancer Prev Res (Phila). 2011 Sep;4(9):1449-56
pubmed: 21680707
J Interferon Cytokine Res. 2013 Oct;33(10):563-70
pubmed: 23697558
Front Oncol. 2021 Aug 13;11:705911
pubmed: 34485137
Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):912-5
pubmed: 20233852
J Clin Oncol. 2012 Jan 10;30(2):151-7
pubmed: 22162577
Circ Res. 2020 May 22;126(11):1549-1564
pubmed: 32437299
J Cancer Res Clin Oncol. 2012 Jun;138(6):999-1009
pubmed: 22362301
PLoS One. 2019 Jan 17;14(1):e0210372
pubmed: 30653559
Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):459-65
pubmed: 25490990